Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2017-08-28 Director's Dealing
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-08-28 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the unregistered sales of equity securities, specifically the conversion of convertible promissory notes into common stock, and details about a registered public offering. It includes no financial statements or comprehensive financial data but rather a specific event related to capital structure changes. The document length is under 5,000 characters and is a standalone filing reporting a financing event. This fits the category of Capital/Financing Update (CAP) rather than a full financial report or other categories.
2017-08-14 English
FORM 10-Q
Interim / Quarterly Report Q3 2017
2017-08-14 English
FORM 4
Director's Dealing
2017-08-10 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the closing of a public offering, including the number of shares and warrants sold, pricing, gross proceeds, and underwriters involved. This is an update on the company's financing activities rather than a full financial report or earnings release. The document length is 3788 characters, which is relatively short and focused on a specific event. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-08-08 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a public offering of common stock and warrants, including underwriting agreements and related details. It also references a press release about the public offering pricing and Nasdaq listing. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is primarily an announcement of a financing event and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6088 characters) supports it being a full filing rather than a brief announcement or certification. Confidence is high given the clear description of a financing transaction and underwriting agreement.
2017-08-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.